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AbstrAct
Introduction. To date, there has been no clear evidence regarding the evaluation of saccades as a monitoring tool of motor 
impairment in Parkinson’s disease (PD) Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) patients. The aim of this study 
was to evaluate the long-term impact of STN-DBS and pharmacological treatment on reflexive saccades’ (RS) parameters and 
UPDRS alterations.
Material and methods. The DBS group consisted of 20 PD patients who underwent bilateral STN-DBS. The Postoperative (POP) 
group consisted of 14 post-DBS patients. The Best Medical Therapy (BMT) group consisted of 20 patients on pharmacotherapy 
only. RS parameters and the UPDRS scale were measured during three visits in four phases of treatment (i.e. BMT-ON/OFF, DBS-
-ON/OFF). 
results. The significant UPDRS III and UPDRS. Total improvements were observed in all three study groups (p < 0.05), but RS 
latency improvement was stated only in the DBS group in the DBS-ON phase (p < 0.05). A significant correlation between RS 
latency increase and UPDRS III score worsening was found in all study groups, with the most evident effect in the UPDRS III ON 
phase (p < 0.05). 
conclusion. RS parameters correlated with UPDRS III outcomes during the postoperative period in DBS-STN patients. Therefore, 
saccadic evaluation may be a good biomarker of the patient’s response to surgical and/or pharmacological treatment. 
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Introduction
Deep brain stimulation (DBS) has become the standard 
surgical procedure in Parkinson’s disease (PD) patients, 
particularly in advanced stages of the disease and with com-
plications after levodopa therapy. The subthalamic nucleus 
(STN) is the most often chosen localisation because of the 
impact on most of the motor symptoms, particularly tremor, 
bradykinesia and rigidity [1–3] as well as because of the po-
ssibility of decreasing the daily levodopa dose [4]. 
STN is a part of the saccadic system, the impairment of 
which influences other structures implicated in the generation 
of saccades, provoking alterations of saccadic movements 
[5–7]. PD patients present abnormalities in random saccades, 
reflexive saccades as well as antisaccades or smooth pursuit 
movements [8–10]. STN-DBS has also been shown to have 
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an observable impact on saccades’ parameters such as latency, 
velocity, amplitude, gain or accuracy [11–17]. Levodopa or 
dopamine agonist treatment has also been shown to have 
a possible influence on saccadic movements, but changes in 
ON-Levodopa state are not clear [18–23], which makes the 
existing evidence more conflicting. Nevertheless, reflexive 
saccades’ (RS) evaluation is a simple method of assessing the 
possible influence of DBS or pharmacotherapy on the saccadic 
system, which can be due to alteration or alleviation of the ba-
lance between direct and indirect dopamine pathways [24, 25].
All randomised studies comparing the quality of life of 
PD patients after STN-DBS implantation to the group of PD 
patients treated with best medical therapy (BMT) in advanced 
[26–28] or early PD [29] have revealed clinically meaningful 
improvements of PDQ-39 score and UPDRS-II, UPDRS-III 
Stim ON evaluation in DBS patients as compared to the BMT-
group in a 6-month [26, 27], 12-month [28], or 24-month [29] 
re-assessment. None of the randomised trials [26–29] has 
compared the mean change in UPDRS-III score between the 
BMT-group and DBS patients in a full OFF phase (BMT-OFF/ 
/DBS-OFF) after DBS implantation — all of the studies have 
evaluated the BMT-OFF/DBS-ON phase only.
The aim of this study was to evaluate the impact of bila-
teral STN-DBS and pharmacological treatment on changes 
in reflexive saccades’ (RS) parameters and the UPDRS scale 
[30] in four phases of treatment (BMT-ON/OFF, DBS-ON/
OFF) and to estimate the possible usefulness of eye movement 
(EM) measurements as a biomarker of PD patients’ response 
to surgical and pharmacological treatment. 
Material and methods
Study concept
Patients enrolled to this study were clinically diagnosed as ha-
ving idiopathic Parkinson’s disease and fulfilled the UK Parkinson’s 
Disease Society (UKPDS) Brain Bank criteria [31]. All of the study 
patients also met the CAPSIT-PD criteria [32] in order to have 
the qualification criteria for bilateral STN DBS implantation. 
The patients were divided into three groups: 
1) The BMT (Best Medical Therapy) group: 20 patients (mean 
age 56.7 years, 11 females, nine males) treated only with 
pharmacotherapy through the whole time of observation. 
2) The DBS (Deep Brain Stimulation) group: 20 patients 
(mean age 51.1 years, eight females, 12 males) who unde-
rwent surgical procedure and pharmacotherapy. 
3) The POP (Postoperative) group: 15 patients (mean age 
51.4 years, seven females, eight males) who had been 
operated upon a median time of 30 months before the 
study began. This group was created in order to estimate 
any possible long-term motor effect of DBS. 
The patients were examined during three visits (V1, V2, 
V3) made at intervals of 7-11 months. The UPDRS scale and 
reflexive saccades were evaluated twice during each visit in the 
BMT-group and preoperative assessment in the DBS-group 
(BMT-ON and BMT-OFF phase), and four times (Total-ON, 
DBS-ON/BMT-OFF, DBS-OFF/BMT-ON, Total-OFF) during 
postoperative evaluations (V2, V3) in the DBS group, and 
during all visits (V1, V2, V3) in the POP group.
The characteristics of the patients are set out in Table 1. 
All of the patients signed informed consents. This study was 
approved by the Ethics Committee of the Medical University of 
Warsaw. The experiments were conducted in accordance with 
the ethical standards of the Declaration of Helsinki.
UPDRS examination and saccadic assessment
The motor evaluation of the patients was performed by 
a neurologist experienced in movement disorders, using the 
UPDRS scale and saccadometry. The assessment was conduc-
ted in different phases of treatment: BMT-ON/DBS-ON when 
patients were on/off antiparkinsonian drugs and (in posto-
perative evaluation) with both stimulators switched on/off. 
Saccadometry was evaluated using a head-mounted sacca-
dometer (Ober Consulting, Poznan, Poland), which analyses 
binocular infra-red reflections from each eye. The saccadic step 
task paradigm was used with 20 calibration saccades followed by 
50 random horizontal points projected in a random fore-period 
of 0.5–1.5s, which were always preceded by fixation central 
points. The parameters analysed were: saccadic latency [ms], sac-
cades’ amplitude [deg], and peak of velocity of saccades [deg/s]. 
The data was analysed using LatencyMeter software, version 6.9.
Surgical procedure
All of the patients who underwent surgery qualified 
for bilateral subthalamic nucleus deep brain stimulation 
table 1. Study population characteristics 
bMt group Dbs group POP group
Gender 11 F, 9 M 8 F, 12 M 7 F, 8 M
Mean age 56.7 ± 15.4 years 51.1 ± 15.3 years 51.4 ± 8.7 years
Mean age at onset 46.3 ± 15.1 years 39.7 ± 13.3 years 40.9 ± 8.3 years
Mean symptoms’ duration time 10.4 ± 4.9 years 11.3 ± 3.9 years 10.5 ± 3.5 years
Mean LEDD 1,254.0 ± 511.6 mg 1,379.5 ± 510.0 mg 1,273.2 ± 464.3 mg
Mean time of dyskinesia 1.8 ± 2.6 hours / day 4.9 ± 2.9 hours / day 5.9 ± 2.6 hours / day
Mean OFF time 2.7 ± 1.3 hours / day 4.6 ± 3.2 hours / day 4.4 ± 1.8 hours / day
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(STN-DBS). The procedure was performed using microre-
cording and macrostimulation (Leadpoint®, Medtronic) and 
permanent electrodes (3389-28, Medtronic, Minneapolis, 
MN, USA) which were connected to internal pulse generators 
(Activa SC, Medtronic).
Data analysis and statistical assessment
The linear mixed model analysis was implemented by the 
use of LME4 (version 1.1) with intercepts for subjects included 
as random effects. Pairwise interactions between each fixed 
factor were included in the model. Tukey contrasts (from 
lsmeans package, version 2.25) were used to compare results 
between timepoints and treatments [33]. All calculations were 
performed in statistical computing software R (version 3.3) 
[34]. P values < 0.05 were considered significant.
Results
The mixed model analysis of RS showed a significant inter-
phase latency difference (p < 0.05) with a visible relation in inter-
visit changes in BMT-ON and DBS-ON phases (p = 0.1). The 
pharmacotherapy (levodopa and other dopaminergic treatment) 
did not significantly influence the saccades latency (p > 0.05). On 
the other hand, bilateral STN-DBS ON significantly improved RS 
latency (regardless of pharmacotherapy phase) in both (short-term 
and long-term) postoperative groups (p < 0.05). There was also 
statistically significant amplitude reduction in the first postopera-
tive (ΔV2-V1) Total-OFF evaluation in DBS group (p < 0.05), 
not observed in other groups and other inter-visit assessments. 
The same results were also found in saccades’ peak velocity: no 
statistically significant inter-phase or inter-visit changes in RS 
peak velocity, other than a definite reduction in peak velocity of 
saccades in the first postoperative (ΔV2-V1) examination of the 
DBS group in Total-OFF phase (p < 0.05) (Fig.1C–E).
The mixed model analysis of inter-phase UPDRS III score 
alterations was statistically significant (p < 0.05), as was the 
analysis of UPDRS III score alterations among visits in all three 
groups of patients (p < 0.05). The inter-phase analysis showed 
a significant improvement in UPDRS III score in Total-ON 
phase (compared to Total-OFF phase) in all three study groups 
(p < 0.05) (Fig. 1A). The improvement was observed in consecu-
tive visits in all study groups (p < 0.05), with a more visible im-
pact of the STN-DBS procedure. The mean inter-phase change 
was more evident in both postoperative groups in phases with 
stimulators switched ON (DBS and POP group) (p < 0.05) 
than in BMT-ON only phase (with stimulators switched off). 
The analysis of inter-phase UPDRS TOTAL score was 
also statistically significant (p < 0.05) as were UPDRS TO-
TAL score changes among visits in the BMT, DBS and POP 
groups (p < 0.05). The improvement of UPDRS TOTAL 
score was observed in all three groups of patients, with the 
most evident effect of STN-DBS procedure in the short-term 
postoperative DBS group (p < 0.05), but was not observed in 
long-term postoperative assessment (POP-group, p > 0.05). 
The mean inter-phase alterations in the UPDRS TOTAL score 
were observed in phases with stimulators switched ON (DBS 
and POP group) rather than in phases with BMT-only ON 
(p < 0.05) ( Fig. 1B).
The mixed model analyses between inter-phase and inter-
visit UPDRS III and saccades’ latency, amplitude and peak 
velocity in the DBS, BMT and POP groups were performed to 
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Figure 1. A. UPDRS III
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in operative and non-operative PD patients. The analyses re-
vealed a statistically significant correlation between RS latency 
increase and UPDRS III score worsening in all study groups, 
with the most evident effect in the UPDRS III ON phase (p 
< 0.05). Such a clear correlation between UPDRS III and RS 
amplitude and / or RS peak velocity was not demonstrated 
(p > 0.05). 
Inter-visit PDQ-39 and AIMS evaluations in all study 
groups were also carried out to compare the influence of surgi-
cal procedure and pharmacotherapy on the patients’ quality of 
life and the level of dyskinesia intensity. The analyses showed 
a significant improvement of quality of life and a decrease of 
AIMS in the short-term postoperative DBS group (p < 0.05), 
which was not observed either in the BMT or the POP group 
ΔV3-V1 assessment (p > 0.05).
Discussion
The motor improvement of PD patients after STN-DBS 
has been previously proven in randomised trials [26–29], but 
to date there has been no clear evidence on UPDRS and RS 
application as biomarkers of STN-DBS treatment. 
345www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Stanisław Szlufik et al., Evaluating reflexive saccades and UDPRS as markers of Deep Brain Stimulation
Figure 1. D. mean RS amplitude, E. mean RS peak velocity in BMT, DBS and POP group (V1, V2, V3). Consecutive phases: Total-ON, DBS-ON/
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In all previous randomised studies, the authors proved 
a great improvement in UPDRS III DBS-ON BMT-OFF eva-
luation in patients after STN-DBS surgery, and a significant 
impact of STN-DBS procedure on quality of life in STN-DBS 
patients [26–29], but none of them compared total OFF phase 
in the DBS group in consecutive examinations. 
In contrast, our study completed this comparison in all 
four treatment phases in order to establish the full impact of 
STN-DBS on UPDRS-III and saccadic alterations in BMT/
STN-DBS PD patients.
Saccadometry was first described as a possibly useful 
clinical tool for the quantification of the motor effects of 
STN-DBS in PD in 2009 by Temel et al. [17], but there were 
also some other prior studies on monkeys and humans which 
showed a potential use of this method as a parametric tool in 
the assessment of motor changes in PD treatment [8, 11, 15, 
16, 18–23]. Because of the fact that STN is a part of the sacca-
dic system, various methods of treatment which influence its 
stimulation can result in alterations of saccadic movements. 
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ON/OFF and BMT ON/OFF in order to estimate the possible 
correlation between motor improvement in UPDRS III scale 
and reflexive saccades’ variations. Our results are consistent 
with previous studies, and show a greater improvement in RS 
latency in the DBS-ON phase (compared to the OFF-phase) 
rather than in the BMT-ON phase (compared to the BMT-
-OFF), which may also be an indicator of a more significant 
effect of STN-DBS, rather than pharmacotherapy, on saccadic 
system alterations. The other clinical problem of using saccadic 
movements’ assessment as a parametric evaluation of motor 
deficits in PD patients under various methods of treatment 
is a lack of information concerning the rate of progression 
of saccadic alterations in PD. The only assessment has been 
performed by Antoniades et al. [13] who examined nine PD 
patients during four visits in order to observe the variations 
of saccades, which were anomalous: first postoperative as-
sessment in OFF-phase revealed deterioration which was 
later improved in the following assessment [13], possibly 
due to astroglial neuroinflammatory reaction to stimulation 
confirmed in recent animal studies [35–37].
Conclusions
The definite improvement of RS latency with significant cor-
relations to UPDRS III and UPDRS TOTAL score improvement 
in DBS-ON phase in both DBS (short and long term postope-
rative) groups with a co-existent non-significant improvement 
in RS latency (but with preserved significant UPDRS III and 
UPDRS TOTAL improvement) in the BMT group in the ON 
phase may suggest that BMT interferes mostly with the dopami-
nergic system, while STN-DBS may affect other systems as well. 
Our results show that the application of RS measurement 
as a parametric tool (apart from UPDRS III assessment, which 
is a subjective scale) may be a good prognostic indicator of 
STN-DBS and pharmacological treatment effect on PD pa-
tients’ motor outcome and quality of life. The limitations of 
our study, i.e. the study group sizes and the restricted duration 
of the study, may necessitate a prolonged assessment on larger 
populations in order to confirm the quality of these results. 
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